Exhibit 107
Calculation of Filing Fee Tables
Form S-4
(Form Type)
TriSalus Life Sciences, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered and Carry Forward Securities
| | | | | | | | | | | | | | | | | |
|
| Security Type |
| Security Class Title |
| Fee Calculation or Carry Forward Rule(1) |
| Amount Registered(2) |
| Proposed Maximum Offering Price Per Unit |
| Maximum Aggregate Offering Price |
| Fee Rate |
| Amount of Registration Fee | |
Newly Registered Securities | |||||||||||||||||
Fees to Be Paid | | Equity | | Warrants to purchase Common Stock | | Other | | 8,281,779 | (3) | $0.8989 | (4) | $7,444,491.14 | (4) | $0.00014760 | | $1,098.81 | |
Fees to Be Paid | | Equity | | Warrants to purchase Common Stock | | Other | | 4,933,333 | (5) | $0.8989 | (6) | $4,434,573.03 | (6) | $0.00014760 | | $654.54 | |
Fees to Be Paid | | Equity | | Warrants to purchase Common Stock | | Other | | 1,000,000 | (7) | $0.8989 | (8) | $898,900.00 | (8) | $0.00014760 | | $132.68 | |
Fees to Be Paid | | Equity | | Warrants to purchase Common Stock | | Rule 457(g) | | 14,215,112 | (9) | N/A | | N/A | | N/A | | — | (10) |
Fees Previously Paid | | — | | — | | — | | — | | — | | — | | | | — | |
| | Total Offering Amounts | | | | $12,777,964.18 | | | | $1,886.03 | | ||||||
| | Total Fees Previously Paid | | | | | | | | — | | ||||||
| | Total Fee Offsets | | | | | | | | — | | ||||||
| | Net Fee Due | | | | | | | | $1,886.03 | |
(1) | As discussed in the Prospectus/Offer to Exchange (the “Prospectus/Offer to Exchange”), which forms a part of the Registration Statement on Form S-4 to which this Exhibit 107 is filed as an exhibit, in lieu of issuing fractional shares, any holder who would otherwise have been entitled to receive fractional shares pursuant to the Offer (as defined in the Prospectus/Offer to Exchange) will, after aggregating all such fractional shares of such holder, be paid in cash (without interest) in an amount equal to such fractional part of a share multiplied by the last sale price of the common stock, par value $0.0001 per share (“Common Stock”), of TriSalus Life Sciences, Inc. (the “Company”) on the Nasdaq Global Market on the last trading day of the Offer Period (as defined in the Prospectus/Offer to Exchange). |
(2) | Pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), the Company is also registering an indeterminate number of additional shares of Common Stock issuable by reason of any stock dividend, stock split, recapitalization or other similar transaction. |
(3) | Represents the Public Warrants (as defined in the Prospectus/Offer to Exchange). |
1
(4) | Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(f)(1) and Rule 457(c) under the Securities Act, utilizing $0.8989, the average of the high and low prices of a Public Warrant on May 21, 2024, as reported on the Nasdaq Global Market. |
(5) | Represents the Private Placement Warrants (as defined in the Prospectus/Offer to Exchange). |
(6) | Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(f)(2) under the Securities Act, utilizing $0.8989, the book value of a Private Placement Warrant, as computed as of May 21, 2024. |
(7) | Represents the Working Capital Warrants (as defined in the Prospectus/Offer to Exchange). |
(8) | Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(f)(2) under the Securities Act, utilizing $0.8989, the book value of a Working Capital Warrant, as computed as of May 21, 2024. |
(9) | Represents the maximum number of Public Warrants, Private Placement Warrants and Working Capital Warrants that may be exchanged in the Offer or amended pursuant to the Warrant Amendment (as defined in the Prospectus/Offer to Exchange). |
(10) | No additional registration fee is payable pursuant to Rule 457(g) under the Securities Act. |
2